 WALTHAM, Mass., Jan. 06, 2021 GLOBE NEWSWIRE -- EyeGate Pharmaceuticals, Inc. NASDAQ: EYEG, EyeGate or the Company, a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that it has entered into a securities purchase agreement in connection with a private placement the Private Placement with an affiliate of Armistice Capital, LLC Armistice for aggregate gross proceeds of approximately 8.0 million. The Private Placement is expected to close on or about January 6, 2021, subject to the satisfaction of customary closing conditions. 